oper line guidanc temper
respect
ep top consensu ep beat
better revenu line profit factor line
drove beat reduc ep guidanc call
lower end previou rang attribut challeng
pharmedium lash ep move
lower revenu profit run rate reflect aforement headwind
tp move lower view
revenu ahead profit par revenu growth vs estimate
driven stronger experi across core distribut
suspens product pharmedium facil rose healthi
vs estimate repres profit key compon
posit thesi gross margin bp bp ahead plan
oper expens bp bp higher plan drive ebitda
margin deterior bp line view key focu area
oper profit distribut improv albeit weaker plan
partial own pharmedium burn million
repurchas million share quarter
share rise view ep upsid stronger
distribut perform encourag focu guidanc
impact on-going interrupt pharmedium temper
guidanc low end rang like better fear
pharmedium
conundrum albeit reflect flat segment ebit growth await
pharmmedium updat call re-affirmed brand gener price
expect encourag data point overal see revenu profit
driver wba matur pharmaci network relationship onboard
relationship contribut
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
price may rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
similar
low end
competit less price
variabl last year
competit less price
competit less price
buysid in-lin expect
slightli msd full-year
higher end
flat mid-singl digit
